These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1568 related articles for article (PubMed ID: 27477897)

  • 1. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
    Kim EH; Shin D; Lee J; Jung AR; Roh JL
    Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL; Kim EH; Jang H; Shin D
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Roh JL; Kim EH; Jang H; Shin D
    Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
    Kim EH; Jang H; Shin D; Baek SH; Roh JL
    Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant Head and Neck Cancer Cells to Ferroptosis.
    Lee J; You JH; Shin D; Roh JL
    Theranostics; 2020; 10(17):7775-7786. PubMed ID: 32685019
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL; Park JY; Kim EH; Jang HJ
    Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer.
    Shin D; Lee J; You JH; Kim D; Roh JL
    Redox Biol; 2020 Feb; 30():101418. PubMed ID: 31931284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
    Kim EH; Jang H; Roh JL
    Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors.
    Zille M; Kumar A; Kundu N; Bourassa MW; Wong VSC; Willis D; Karuppagounder SS; Ratan RR
    eNeuro; 2019; 6(1):. PubMed ID: 30783618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
    Roh JL; Kim EH; Park JY; Kim JW
    Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
    Kim EH; Baek S; Shin D; Lee J; Roh JL
    Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
    Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
    Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines.
    Zheng J; Sato M; Mishima E; Sato H; Proneth B; Conrad M
    Cell Death Dis; 2021 Jul; 12(7):698. PubMed ID: 34257282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
    Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
    Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLC7A11 as a biomarker and therapeutic target in HPV-positive head and neck Squamous Cell Carcinoma.
    Hémon A; Louandre C; Lailler C; Godin C; Bottelin M; Morel V; François C; Galmiche A; Saidak Z
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1083-1087. PubMed ID: 33019976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.